HR-positive, HER2-negative breast cancer
Clinical trials for HR-positive, HER2-negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR-positive, HER2-negative breast cancer trials appear
Sign up with your email to follow new studies for HR-positive, HER2-negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC